



## **Centre for AIDS Reagents**

## **Data Sheet**

NAME:	TZM-bl/ Fc?RIIIa
REPOSITORY REFERENCE:	ARP5031
SPECIES/TYPE:	Human/HeLa
DESCRIPTION:	This is a derivative of the TZM-bl cell line, engineered by lentiviral transduction to stably express human Fc?RIIa on the surface. The parent TZM-bl cell line is an engineered HeLa cell clone that expresses human CD4, CCR5 and CXCR4 and contains HIV-1 Tat-regulated reporter genes for firefly luciferase and \(\mathbeloe{B}\)-galactosidase (TZM-bl cells, Cat# 8129, NIH AIDS Research and Reference Reagent Program). TZM-bl/Fc?RIIa cells remain highly sensitive to infection with diverse isolates of HIV and SIV.
	PLEASE NOTE: The TZM-bl cell line is contaminated with ecotropic murine leukemia virus, MLV. For additional information please consult the following reference (Takeuchi et. al, 2008).
SPECIAL CHARACTERISTICS:	Expression of Fc?RIIa on this cell line facilitates studies of the Fc portion of antibody in mediating HIV-1 neutralization and infection-enhancement in vitro. Optimal sensitivity to infection is achieved by including DEAEdextran in the medium. The original TZM-bl cell line was found to be infected with an ecotropic murine leukemia virus, but this has had no measurable effect on the outcome of HIV infection and neutralization assays.
CULTURE MEDIUM:	DMEM (90%), 10% FBS, 0.025M Hepes buffer, 10 $\mu$ g/mL Gentamicin
STORAGE:	Liquid nitrogen
SOURCE:	Dr. David Montefiori and Dr. Gabriel Perez (Courtesy of the NIH)



National Institute for Biological Standards and Control – Assuring the quality of biological medicines
Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG United Kingdom
Tel +44 (0)1707 641000 Fax +44 (0)1707 641050 www.nibsc.ac.uk
A World Health Organization Laboratory for Biological Standards

Perez LG, et al. J. Virol. 83:7397-7410, 2009

**REFERENCE:** 





Platt EJ, et al. J. Virol 83: 8289-8292, 2009

Takeuchi Y, McClure MO, Pizzato M. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research., J Virol. 2008 Dec;82(24):12585-8.

## **ACKNOWLEDGEMENTS:**

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <a href="http://www.nibsc.ac.uk/spotlight/centre\_for\_aids\_reagents.aspx">http://www.nibsc.ac.uk/spotlight/centre\_for\_aids\_reagents.aspx</a> in the "Acknowledgements" section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)